NASDAQ:ILMN

Illumina Stock Forecast, Price & News

$401.96
+3.89 (+0.98 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$399.62
Now: $401.96
$407.72
50-Day Range
$368.96
MA: $408.24
$461.05
52-Week Range
$260.42
Now: $401.96
$555.77
Volume972,690 shs
Average Volume1.20 million shs
Market Capitalization$58.65 billion
P/E Ratio93.26
Dividend YieldN/A
Beta1.14
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is headquartered in San Diego, California.
Illumina logo

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:ILMN
CUSIP45232710
Phone858-202-4500
Employees7,800
Year Founded1998

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.54 billion
Cash Flow$9.14 per share
Book Value$31.38 per share

Profitability

Net Income$1.00 billion

Miscellaneous

Market Cap$58.65 billion
Next Earnings Date4/27/2021 (Confirmed)
OptionableOptionable

Headlines

Is Illumina Still a Buy Without the GRAIL Acquisition?
April 15, 2021 |  finance.yahoo.com
Illumina (NASDAQ:ILMN) Price Target Raised to $330.00
April 13, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.64 out of 5 stars

Medical Sector

334th out of 2,021 stocks

Analytical Instruments Industry

8th out of 29 stocks

Analyst Opinion: 2.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$401.96
+3.89 (+0.98 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ILMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Illumina (NASDAQ:ILMN) Frequently Asked Questions

Is Illumina a buy right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 4 sell ratings, 8 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Illumina stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View analyst ratings for Illumina
or view top-rated stocks.

What stocks does MarketBeat like better than Illumina?

Wall Street analysts have given Illumina a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Illumina wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Illumina's next earnings date?

Illumina is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021.
View our earnings forecast for Illumina
.

How can I listen to Illumina's earnings call?

Illumina will be holding an earnings conference call on Tuesday, April 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) posted its quarterly earnings results on Thursday, February, 11th. The life sciences company reported $1.22 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.11 by $0.11. The life sciences company earned $953 million during the quarter, compared to analyst estimates of $949.65 million. Illumina had a trailing twelve-month return on equity of 15.93% and a net margin of 19.70%.
View Illumina's earnings history
.

How has Illumina's stock been impacted by Coronavirus?

Illumina's stock was trading at $246.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ILMN shares have increased by 63.4% and is now trading at $401.96.
View which stocks have been most impacted by COVID-19
.

What guidance has Illumina issued on next quarter's earnings?

Illumina issued an update on its first quarter 2021 After-Hours earnings guidance on Monday, April, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.085-1.085 billion, compared to the consensus revenue estimate of $924.6 million.

What price target have analysts set for ILMN?

18 brokers have issued twelve-month price objectives for Illumina's shares. Their forecasts range from $280.00 to $570.00. On average, they anticipate Illumina's share price to reach $370.58 in the next twelve months. This suggests that the stock has a possible downside of 7.8%.
View analysts' price targets for Illumina
or view top-rated stocks among Wall Street analysts.

Who are Illumina's key executives?

Illumina's management team includes the following people:
  • Mr. Francis A. deSouza, CEO, Pres & Director (Age 50) (LinkedIn Profile)
  • Mr. Sam A. Samad, Chief Financial Officer (Age 51, Pay $626.7k) (LinkedIn Profile)
  • Dr. Joydeep Goswami, Sr. VP of Corp. Devel. & Strategic Planning (Age 50, Pay $384.38k) (LinkedIn Profile)
  • Ms. Aimee L. Hoyt, Chief People Officer (Age 49, Pay $864.07k) (LinkedIn Profile)
  • Mr. Robert P. Ragusa, Chief Operations Officer (Age 61) (LinkedIn Profile)
  • Ms. Karen K. McGinnis CPA, VP & Chief Accounting Officer (Age 54)
  • Dr. Alexander Aravanis M.D., Ph.D., Chief Technology Officer (LinkedIn Profile)
  • Mr. Steve Phillpott, Sr. VP & Chief Information Officer
  • Ms. Juliet Cunningham, VP of Investor Relations (LinkedIn Profile)
  • Mr. Charles E. Dadswell, Gen. Counsel (Age 62) (LinkedIn Profile)

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina CEO Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among Illumina's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Illumina's key competitors?

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), The Walt Disney (DIS), PayPal (PYPL), salesforce.com (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by many different institutional and retail investors. Top institutional investors include Royal London Asset Management Ltd. (0.09%), Retirement Systems of Alabama (0.05%), Gateway Investment Advisers LLC (0.04%), FDx Advisors Inc. (0.04%), Capital Investment Services of America Inc. (0.04%) and DnB Asset Management AS (0.02%). Company insiders that own Illumina stock include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi.
View institutional ownership trends for Illumina
.

Which major investors are selling Illumina stock?

ILMN stock was sold by a variety of institutional investors in the last quarter, including FDx Advisors Inc., Retirement Systems of Alabama, First Hawaiian Bank, Pacer Advisors Inc., State of Alaska Department of Revenue, Crossmark Global Holdings Inc., Gateway Investment Advisers LLC, and Canton Hathaway LLC. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Phillip G Febbo, Robert P Ragusa, Sam Samad, and Susan H Tousi.
View insider buying and selling activity for Illumina
or view top insider-selling stocks.

Which major investors are buying Illumina stock?

ILMN stock was bought by a variety of institutional investors in the last quarter, including Royal London Asset Management Ltd., FDx Advisors Inc., Everence Capital Management Inc., DnB Asset Management AS, Anderson Hoagland & Co., Capital Investment Services of America Inc., NuWave Investment Management LLC, and Louisiana State Employees Retirement System.
View insider buying and selling activity for Illumina
or or view top insider-buying stocks.

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $401.96.

How much money does Illumina make?

Illumina has a market capitalization of $58.65 billion and generates $3.54 billion in revenue each year. The life sciences company earns $1.00 billion in net income (profit) each year or $6.57 on an earnings per share basis.

How many employees does Illumina have?

Illumina employs 7,800 workers across the globe.

Does Illumina have any subsidiaries?

The following companies are subsidiares of Illumina: Advanced Liquid Logic, Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Edico Genome Corp., Enancio, Epicentre Biotechnologies, Epicentre Technologies Corporation, FC Ops Corp., GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada Inc., Illumina Denmark ApS, Illumina Finland Oy, Illumina France Holding Sarl, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina Iceland ehf, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus, Illumina Shanghai (Trading) Co Ltd, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.

When was Illumina founded?

Illumina was founded in 1998.

What is Illumina's official website?

The official website for Illumina is www.illumina.com.

Where are Illumina's headquarters?

Illumina is headquartered at 200 ILLUMINA WAY, SAN DIEGO CA, 92122.

How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.